SCHEMBL23326346

SCHEMBL23326346

O=c1c(N2CCOCC2)cc2c(Cl)ncnc2n1C1CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 4/20 0.52
CYP1A2 P05177 9/20 0.42
ALDH1A1 P00352 8/20 0.42
HSD17B10 Q99714 5/20 0.42
CYP3A4 P08684 4/20 0.42
MEN1 O00255 9/20 0.40
KMT2A Q03164 9/20 0.40
HIF1A Q16665 3/20 0.40
USP2 O75604 3/20 0.40
ALOX15 P16050 2/20 0.40
HPGD P15428 1/20 0.40
CLK4 Q9HAZ1 4/20 0.40
CASP1 P29466 5/20 0.39
CASP7 P55210 5/20 0.39
CYP2C9 P11712 2/20 0.39
GLA P06280 2/20 0.39
PRKDC P78527 1/20 0.38
CYP2C19 P33261 2/20 0.37
TSHR P16473 1/20 0.36
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326348 0.81 SOS1 (0.51) SOS1CYP1A2ALDH1A1HSD17B10CYP3A4
SCHEMBL23326451 0.76 CYP1A2 (0.38) CYP1A2ALDH1A1CYP3A4ALOX15HPGD
SCHEMBL29861603 0.76 CYP1A2 (0.38) CYP1A2ALDH1A1CYP3A4ALOX15HPGD
SCHEMBL23326487 0.70 SOS1 (1.00) SOS1
SCHEMBL26131655 0.68 ALDH3A1 (0.38) CYP1A2ALDH1A1HSD17B10CYP3A4KMT2A
SCHEMBL23326598 0.67 SOS1 (0.51) SOS1CYP1A2ALDH1A1HSD17B10CYP3A4
SCHEMBL2423850 0.64 PRKDC (0.47) CYP1A2ALDH1A1HSD17B10CYP3A4ALOX15
SCHEMBL26131236 0.63 ALDH1A1 (0.40) ALDH1A1HSD17B10MEN1KMT2AALOX15
SCHEMBL28494938 0.62 LRRK2 (0.40) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL24312145 0.61 MAPT (0.45) CYP1A2ALOX15PRKDCTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 EP disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 SOS1 1/4885CYP1A2 1997/4885ALDH1A1 3199/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 SOS1 2/4885CYP1A2 2086/4885ALDH1A1 3594/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 SOS1 2/4885CYP1A2 2086/4885ALDH1A1 3594/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 SOS1 2/4885CYP1A2 2086/4885ALDH1A1 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.